Gavin Little, DO
Internal Medicine · Stratham, NHNPI 1598792004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 349 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 349 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$990
- AstraZeneca$620
- Boehringer Ingelheim$520
- Lilly USA, LLC$437
- GSK$405
- AbbVie$347
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,33597%
- Education$1683%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 68 | $990 |
| AstraZeneca | 37 | $620 |
| Boehringer Ingelheim | 31 | $520 |
| Lilly USA, LLC | 34 | $437 |
| GSK | 25 | $405 |
| AbbVie(2 entities) | 24 | $347 |
| Merck | 15 | $247 |
| Astellas Pharma US Inc | 11 | $229 |
| Novo Nordisk | 15 | $202 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $188 |
| Avanir Pharmaceuticals, Inc. | 7 | $131 |
| Scilex Pharmaceuticals Inc. | 8 | $129 |
| Amgen | 7 | $119 |
| Supernus Pharmaceuticals, Inc. | 7 | $112 |
| Teva Pharmaceuticals USA, Inc. | 7 | $108 |
| Johnson & Johnson | 5 | $95 |
| Esperion Therapeutics, Inc. | 4 | $75 |
| Novartis | 4 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 3 | $53 |
| Biohaven Pharmaceuticals, Inc. | 3 | $51 |
| Lundbeck LLC | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Jazz Pharmaceuticals Inc. | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 2 | $29 |
| GE HealthCare | 1 | $23 |
| Medtronic | 1 | $22 |
| Eisai Inc. | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Alkermes, Inc. | 1 | $13 |
How this compares
$5,503 in reported general payments places this provider in the 95th percentile of 504 internal medicine providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $59,393 |
| EliquisApixaban | 37 | $47,103 |
| XareltoRivaroxaban | 12 | $17,407 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $15,494 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $3,918 |
| Atorvastatin Calcium | 246 | $2,594 |
| Aripiprazole | 13 | $2,255 |
| Levothyroxine Sodium | 142 | $1,982 |
| SynthroidLevothyroxine Sodium | 17 | $1,925 |
| Valsartan | 31 | $1,897 |
| Amitriptyline Hcl | 26 | $1,175 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 19 | $1,107 |
| Bupropion XlBupropion Hcl | 41 | $1,033 |
| Lisinopril | 131 | $1,027 |
| Rosuvastatin Calcium | 95 | $1,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $202 | $59,39343 claims |
| PfizerEliquis | $990 | $47,10337 claims |
| Johnson & JohnsonXarelto | $95 | $17,40712 claims |
| GSKTrelegy Ellipta | $405 | $15,49417 claims |
| AstraZenecaSymbicort | $620 | $3,91817 claims |
| AbbVieSynthroid | $347 | $1,92517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 504 internal medicine providers in New Hampshire.
Other internal medicine in Stratham
- Donald RainoneLondonderry$1.9M
- Brian HyettPortsmouth$185K
- Deborah TepperLebanon$133K
- Mark HenschkeNewington$114K
- William MonacoLebanon$97K
- Kevin PhoNashua$40K
- Mary McGowanLebanon$26K
- Magued Rizkalla HannaPortsmouth$26K
- Daniel FeldmanLebanon$17K
- Jonathan BridgesNewington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.